Enanta Pharma (ENTA) Tops Q3 EPS by 36c

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($1.07), $0.36 better than the analyst estimate of ($1.43). Revenue for the quarter came in at $18 million versus the consensus estimate of $17.44 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• UBS: 'We expect SpaceX shares to continue to trade on demand for tokens'